Table 4.
Two-year survival rates after postoperative vaccination with ATV-NDV. n Number of patients
| Tumor type | Stage | Two-year survival rate | Increase of survival rate (%) | Significance (p) | |
|---|---|---|---|---|---|
| Colorectal carcinoma | |||||
| Median follow-up 22 months | (a) Locally advanced d | Controla (n=601, 74%) | Vaccinated (n=48, 98%) | 24 | |
| Median follow-up 18 months | (b) Solitary livere metastases, RO resectable | Controlb (n=23, 61%) | Vaccinated (n=23, 87%) | 26 | 0.05 |
| Glioblastoma multiforme | |||||
| Median follow-up 59 months | Grade IVf | Controlb (n=87, 11%) | Vaccinated (n=23, 39%) | 28 | <0.001 |
| Malignant melanoma | |||||
| Median follow-up 18 months | Recurrent resectableg | Vaccinated c (a) ATV-NDV <3×106 (n=20, 45%) | Vaccinated (b) ATV-NDV >3×106 (n=21, 65%) | 20 | |
aHistorical control from the same clinic
bPair-matched controls
cThis control group was vaccinated with a vaccine containing less than the indicated number of tumor cells and less than 33% cell viability. It is not historical but an actual internal control
dFrom [55]
eRecurrence-free survival data from [52, 60]
fFrom [62]
gFrom [6]